Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024.
Follow HLN
Alert me
Haleon PLC Sponsored ADR (HLN) P/E ratio
As of 6 November 2026, Haleon PLC Sponsored ADR (HLN) trades at a P/E ratio of 20.5×. Over the past ten years it has ranged from 19.2× (October 2026) to 26.3× (September 2024); the current reading is higher than 12% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.7× | 5.97% |
| FY2024 | 21.4× | 4.13% |
| FY2023 | 20.5× | 0.00% |
| FY2022 | 20.5× | 0.00% |
| FY2021 | 20.5× | 0.00% |
| FY2020 | 20.5× | 0.00% |
| FY2019 | 20.5× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 23.7× | 15.48% |
| Mar 2024 | 20.5× | 0.00% |
| Sep 2023 | 20.5× | 0.00% |
| Jun 2023 | 20.5× | 0.00% |
| 1 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VTRS Viatris Inc. compare | n/m |
| ELAN Elanco Animal Health Incorporated compare | n/m |
| ZTS Zoetis Inc. compare | 13.5× |
| UTHR United Therapeutics Corporation compare | 19.6× |
| HLN Haleon PLC Sponsored ADR | 20.5× |
| NBIX Neurocrine Biosciences, Inc. compare | 23.6× |
| TAK Takeda Pharmaceutical Co. compare | 31.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 45.4× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 93.7× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on HLN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- Beneish M-score
- The full statement